CAPR (Capricor Therapeutics) 3-Year Sortino Ratio: 2.56 (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAPR Capricor Therapeutics Inc CAPR
27 GF Score
Price $6.29
! 3 Warning Signs
View Full Analysis

What is Capricor Therapeutics 3-Year Sortino Ratio?

Capricor Therapeutics CAPR -7.91% 27 3-Year Sortino Ratio is 2.56 as of Aug. 23, 2026. GuruFocus rates CAPR with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

The 3-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past three years. As of today (2026-08-23), Capricor Therapeutics's 3-Year Sortino Ratio is 2.56.

Capricor Therapeutics  (NAS:CAPR) 3-Year Sortino Ratio Explanation

The 3-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past three year. It is calculated as the annualized result of the average three-year monthly excess returns divided by the standard deviation of negative returns in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.

Capricor Therapeutics 3-Year Sortino Ratio Related Terms

CAPR vs DRTS, SPTX, SVRA: 3-Year Sortino Ratio Comparison

For the Biotechnology subindustry, Capricor Therapeutics's 3-Year Sortino Ratio, along with its competitors' market caps and 3-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Capricor Therapeutics 3-Year Sortino Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's 3-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's 3-Year Sortino Ratio falls into.


CAPR
27GF Score
Capricor Therapeutics Inc CAPR
3-Year Sortino Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Capricor Therapeutics 3-Year Sortino Ratio Calculation

The 3-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last three year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 3-Year Sortino Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past three year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.

Frequently Asked Questions Learn more about 3-Year Sortino Ratio →
What does a 3-Year Sortino Ratio of 2.56 mean?
Capricor Therapeutics (CAPR) has a 3-Year Sortino Ratio of 2.56 as of Aug. 23, 2026. 3-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past three years. View historical data for Capricor Therapeutics and its competitors.
Is Capricor Therapeutics' 3-Year Sortino Ratio too high?
Capricor Therapeutics' current 3-Year Sortino Ratio is 2.56. Overall, Capricor Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' 3-Year Sortino Ratio compare to DRTS and SPTX?
Capricor Therapeutics' 3-Year Sortino Ratio of 2.56 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Sortino Ratio for a Biotechnology company?
A good 3-Year Sortino Ratio depends on the Biotechnology industry context. However, 3-Year Sortino Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Sortino Ratio mean?
A high 3-Year Sortino Ratio can signal that a stock is expensive relative to its fundamentals. 3-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past three years. View historical data for Capricor Therapeutics and its competitors. Capricor Therapeutics's current 3-Year Sortino Ratio is 2.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Capricor Therapeutics (CAPR) has a current 3-Year Sortino Ratio of 2.56. The current 3-Year Sortino Ratio is 2.56. Capricor Therapeutics' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Sortino Ratio calculated?
3-Year Sortino Ratio is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current 3-Year Sortino Ratio is 2.56 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Capricor Therapeutics Business Description

Other Exchanges 4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
27GF Score

Get the complete analysis for CAPR

3-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.29
Price